About Trilligant
Helping clients streamline the drug discovery process.
I will explain how to utilize the latest tools and technologies, including machine learning, natural language processing (NLP), and artificial intelligence (AI), to advance your molecular entity discovery programs. As a scientific leader, I leverage data and advanced analytics with impact from research to FDA approval.
While collaborating with pharmaceutical and biotech partners worldwide, my capabilities include computer-aided drug design, due diligence and program strategy.
The name “trilligant” came from
I am passionate about science end leveraging data and AI to accelerate the discovery of medicines. I also have an undergraduate degree in classical piano and am a lover of animals. My post executive life is focused on three main areas: 1) philanthropy in the areas of arts and 2) animals whilst maintaining my life-long love of 3) computational sciences. As such, “Trilligant” has multiple meanings:
1. “Trill” has a dual meaning: it is both the sound that a bird makes and it’s a rapid alternation of musical notes
2. “li” is gender neutral
3. “gan” stands for generative adversarial networks which is a nod to the utility of artificial intelligence
4. “ant” is the name of my husband. Ant is a huge supporter of my crazy endeavors.
Meet Georgia
Georgia McGaughey, Ph.D.
After spending the past 27 years devoting her life to the discovery and advancement of new molecular entities, Dr. McGaughey started Trilligant in 2024. Her distinguished scientific career includes tenures with three pharmaceutical companies, during which she made significant contributions while serving in various leadership roles, including her most recent position as Vice President and Global Head of Data and Computational Sciences at Vertex Pharmaceuticals.
During her career, Dr. McGaughey has contributed to the invention and advancement of several clinical candidates and generated more than 100 publications and presentations. She has been an advisory board member for numerous organizations, scientific journals, and conferences, and has participated in multiple study sections for the NIH. Presently, Dr. McGaughey is open to leveraging her skill set, experience, and perspective while serving as an Independent Director on boards seeking digital transformation guidance, including those in the healthcare sector.
After earning a PhD in Physical Chemistry, she completed a post-doctoral studies program with an emphasis on Electronic Structure Theory. Dr. McGaughey is also a Graduate of the Harvard Business School. In addition to being an avid long-distance runner, she enjoys playing the piano and mentoring high school and college students in the Boston community.